(Z,2R,3R,7R,8S)-2-benzyl-3,7-dihydroxy-8-[(2-methylpropan-2-yl)oxycarbonylamino]-9-[4-[(2-methylpropan-2-yl)oxy]phenyl]non-4-enoic acid | 479496-01-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (Z,2R,3R,7R,8S)-2-benzyl-3,7-dihydroxy-8-[(2-methylpropan-2-yl)oxycarbonylamino]-9-[4-[(2-methylpropan-2-yl)oxy]phenyl]non-4-enoic acid
• CAS: 479496-01-0
• 化学式: C₃₁H₄₃NO₇
• 分子量: 541.685
• InChiKey: HIUOKWHMZZRRSS-LCFAXWLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  39
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (Z,2R,3R,7R,8S)-2-benzyl-3,7-dihydroxy-8-[(2-methylpropan-2-yl)oxycarbonylamino]-9-[4-[(2-methylpropan-2-yl)oxy]phenyl]non-4-enoic acid 、 Fmoc-L-苯丙氨酸 在 哌啶 、 rink amide AM resin 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 N-羟基-7-氮杂苯并三氮唑 、 rink amide AM resin 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 various solvent(s) 为溶剂， 反应 1.33h， 以66%的产率得到(Z)-8-amino-2-benzyl-3,7-dihydroxy-9-(4-hydroxy-phenyl)-non-4-enoic acid (1-carbamoyl-2-phenyl-ethyl)-amide
  参考文献：
  名称：

  High-Affinity Mu Opioid Receptor Ligands Discovered by the Screening of an Exhaustively Stereodiversified Library of 1,5-Enediols

  摘要：

  In this communication, we report the synthesis of an exhaustively stereodiversified library of 16 1,5-enediols (2) and the screening of these compounds for mu opioid receptor (MOR) binding. The stereochemical configuration of 2 strongly impacted the binding affinity, and (S,S,S,R)-2 exhibited a Ki of 8.8 nM for MOR, comparable to that of endomorphin-2 (Ki = 1.2 nM). Moreover, compounds 2 exhibited 5-86-fold selectivity for MOR over delta opioid receptor (DOR) and 16-150-fold selectivity for MOR over kappa opioid receptor (KOR). Additionally, analogues of 2 were synthesized which showed the importance of the trans olefin for receptor binding but that modifications of the C-terminal amino acid were well tolerated. Ligand 11 is noteworthy because it retains only one of the amide bonds present in 1, but binds MOR with an affinity of 10 nM and 110- and 600-fold selectivity for MOR over DOR and KOR. These results demonstrate the utility of stereochemical diversity in the discovery of bioactive small molecules.

  DOI：

  10.1021/ja027150p
• 作为产物：
  描述：

  2-benzyl-3-hydroxy-pent-4-enoic acid 在 吡啶 、 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 4-二甲氨基吡啶 、 lithium hydroxide 、 氢氟酸 、 双氧水 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 3.5h， 生成 (Z,2R,3R,7R,8S)-2-benzyl-3,7-dihydroxy-8-[(2-methylpropan-2-yl)oxycarbonylamino]-9-[4-[(2-methylpropan-2-yl)oxy]phenyl]non-4-enoic acid
  参考文献：
  名称：

  High-Affinity Mu Opioid Receptor Ligands Discovered by the Screening of an Exhaustively Stereodiversified Library of 1,5-Enediols

  摘要：

  In this communication, we report the synthesis of an exhaustively stereodiversified library of 16 1,5-enediols (2) and the screening of these compounds for mu opioid receptor (MOR) binding. The stereochemical configuration of 2 strongly impacted the binding affinity, and (S,S,S,R)-2 exhibited a Ki of 8.8 nM for MOR, comparable to that of endomorphin-2 (Ki = 1.2 nM). Moreover, compounds 2 exhibited 5-86-fold selectivity for MOR over delta opioid receptor (DOR) and 16-150-fold selectivity for MOR over kappa opioid receptor (KOR). Additionally, analogues of 2 were synthesized which showed the importance of the trans olefin for receptor binding but that modifications of the C-terminal amino acid were well tolerated. Ligand 11 is noteworthy because it retains only one of the amide bonds present in 1, but binds MOR with an affinity of 10 nM and 110- and 600-fold selectivity for MOR over DOR and KOR. These results demonstrate the utility of stereochemical diversity in the discovery of bioactive small molecules.

  DOI：

  10.1021/ja027150p

文献信息

• [EN] MU OPIOID RECEPTOR LIGANDS: METHODS OF USE AND SYNTHESIS<br/>[FR] LIGANDS DE RECEPTEUR OPIOIDE MU: PROCEDES D'UTILISATION ET DE SYNTHESE
  申请人：HARVARD COLLEGE

  公开号：WO2004033414A1

  公开（公告）日：2004-04-22

  Peptidomimetic compounds derived from aralkyl substitued 8-amino-3,7- or 3,6-dihydroxy alkenoic or alkanoic acids and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of the mu opioid receptor (MOR) through their binding affinity with that receptor.

  本文描述了从芳基取代的8-氨基-3,7-或3,6-二羟基烯酸或烷酸衍生的肽类模拟化合物，以及包括这些化合物的组合物，以及使用和制备这些化合物的方法。这些化合物在治疗应用中很有用，包括调节受试者（例如，哺乳动物、人类、狗、猫、马）的疾病症状。这些化合物通过它们与μ阿片受体（MOR）的结合亲和力在调节MOR方面很有用。
• Mu opioid receptor ligands: methods of use and synthesis
  申请人：Harrison Bryce A.

  公开号：US20090093534A1

  公开（公告）日：2009-04-09

  Novel compounds and compositions including those compounds, as well as methods of using and making the compounds are herein described. The compounds are useful in therapeutic applications, including modulation of disease or disease symptoms in a subject (e.g., mammal, human, dog, cat, horse). The compounds are useful as modulators of the mu opioid receptor (MOR) through their binding affinity with that receptor.

  本文描述了包括这些化合物在内的新型化合物和组合物，以及使用和制造这些化合物的方法。这些化合物在治疗应用中有用，包括调节受试者（例如哺乳动物、人类、狗、猫、马）的疾病或疾病症状。这些化合物通过它们与μ阿片受体（MOR）的结合亲和力作为MOR的调节剂是有用的。
• US7223888B2
  申请人：——

  公开号：US7223888B2

  公开（公告）日：2007-05-29
• US7759514B2
  申请人：——

  公开号：US7759514B2

  公开（公告）日：2010-07-20
• High-Affinity Mu Opioid Receptor Ligands Discovered by the Screening of an Exhaustively Stereodiversified Library of 1,5-Enediols
  作者：Bryce A. Harrison、Tiffany Malinky Gierasch、Claire Neilan、Gavril W. Pasternak、Gregory L. Verdine

  DOI：10.1021/ja027150p

  日期：2002.11.1

  In this communication, we report the synthesis of an exhaustively stereodiversified library of 16 1,5-enediols (2) and the screening of these compounds for mu opioid receptor (MOR) binding. The stereochemical configuration of 2 strongly impacted the binding affinity, and (S,S,S,R)-2 exhibited a Ki of 8.8 nM for MOR, comparable to that of endomorphin-2 (Ki = 1.2 nM). Moreover, compounds 2 exhibited 5-86-fold selectivity for MOR over delta opioid receptor (DOR) and 16-150-fold selectivity for MOR over kappa opioid receptor (KOR). Additionally, analogues of 2 were synthesized which showed the importance of the trans olefin for receptor binding but that modifications of the C-terminal amino acid were well tolerated. Ligand 11 is noteworthy because it retains only one of the amide bonds present in 1, but binds MOR with an affinity of 10 nM and 110- and 600-fold selectivity for MOR over DOR and KOR. These results demonstrate the utility of stereochemical diversity in the discovery of bioactive small molecules.